Brokerages Set Cencora, Inc. (NYSE:COR) PT at $306.33

Cencora, Inc. (NYSE:COR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven brokerages that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $306.33.

Several analysts have recently weighed in on COR shares. Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Robert W. Baird increased their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. Citigroup increased their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, UBS Group increased their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th.

Cencora Price Performance

Shares of COR traded down $4.43 during mid-day trading on Tuesday, hitting $298.07. 1,159,006 shares of the company were exchanged, compared to its average volume of 1,505,766. Cencora has a 1-year low of $218.65 and a 1-year high of $309.35. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The company has a 50 day moving average of $291.41 and a 200-day moving average of $268.32. The stock has a market cap of $57.77 billion, a price-to-earnings ratio of 34.58, a price-to-earnings-growth ratio of 1.47 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. Cencora's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.80 EPS. Analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares in the company, valued at $91,271,982.06. This trade represents a 4.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer owned 47,582 shares in the company, valued at $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock valued at $9,812,296 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cornerstone Planning Group LLC increased its stake in Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after purchasing an additional 48 shares during the period. Hoey Investments Inc. acquired a new position in Cencora in the first quarter valued at $28,000. Costello Asset Management INC acquired a new position in Cencora in the first quarter valued at $28,000. Banque Transatlantique SA acquired a new position in Cencora in the fourth quarter valued at $29,000. Finally, SBI Securities Co. Ltd. acquired a new position in Cencora in the fourth quarter valued at $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.